Patent intelligence · US
US 11324822
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
Patent details — US 11324822
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 10, 2022
- Expiration
- May 5, 2042
- Applicant
- Syndax Pharmaceuticals, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 11324822 (Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer) is held by Syndax Pharmaceuticals, Inc.. Status: granted. Granted May 10, 2022. Expires May 5, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Syndax Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/4406, A61K39/39541
More from Syndax Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12168054
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
granted -
US 12000829
Selection of patients for combination therapy
granted -
US 11919901
Inhibitors of the menin-MLL interaction
granted -
US 11397184
Selection of patients for combination therapy
granted -
US 10226472
Methods for the treatment of breast cancer
granted
Frequently asked questions
What is US patent 11324822?
US 11324822 (Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer) is held by Syndax Pharmaceuticals, Inc.. Status: granted. Granted May 10, 2022. Expires May 5, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11324822?
Syndax Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11324822 expire?
Our index shows an expiration date of May 5, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.